Pfizer's $1.575 billion acquisition of AstraZeneca's business

Source: on August 25, 2016, Pfizer, a US pharmaceutical company, plans to acquire the anti infection small molecule business of AstraZeneca, a British pharmaceutical company, with a transaction amount of US $1.575 billion The business portfolio of the acquisition includes the approved antibiotics Merrem, zinforo and zavicefta, as well as atm-avi and CXL in the clinical research and development stage According to the acquisition agreement, Pfizer will pay $550 million to AstraZeneca when the transaction is concluded, and a further unconditional payment of $175 million in January 2019, plus $250 million in phased payments, up to $600 million in sales related and recurring payments, as well as future sales of zavicefta and atm-avi in some Markets Two digit royalty of The acquisition does not involve AstraZeneca's bio anti infective portfolio, or the Alzheimer's project the company sold last year John young, head of Pfizer's acquisition program, said the drugs will make the company's operations "basically healthy" because most of the products it sells have lost patent protection The company already has more than 60 combinations of anti infective and anti fungal drugs In addition, Luke miels, executive vice president of AstraZeneca Europe, said: these drugs under Pfizer will reach more patients around the world It is understood that AstraZeneca likes to sell any assets that are no longer core businesses Since Pascal soriot took office as CEO, the company has adopted external authorization strategy to eliminate non core assets, such as selling the once critical Alzheimer's disease project to Lilly, and splitting the antibiotic R & D department Waltham into independent companies after no one paid attention to selling the antibiotic assets According to the past data, Zhitong finance and economics learned that Pfizer had launched a takeover offer to AstraZeneca in 2014, offering £ 60 billion and £ 69.4 billion respectively, but all of them were rejected by AstraZeneca For this acquisition, market analysts pointed out that Pfizer's purchase of AstraZeneca is impure, and the most direct reason may be tax avoidance